Rebus Holdings, Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223029708 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $5.000K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $4.000K
Receivables
Other Receivables
Total Short-Term Assets $9.000K
YoY Change -96.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.000K
Total Long-Term Assets $0.00
Total Assets $9.000K
YoY Change -96.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $2.120M
YoY Change 3.36%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.619M
YoY Change -8.75%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.619M
Total Long-Term Liabilities
Total Liabilities $5.619M
YoY Change -13.13%
SHAREHOLDERS EQUITY
Retained Earnings -$66.00M
YoY Change -0.37%
Common Stock $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.610M
YoY Change
Total Liabilities & Shareholders Equity $9.000K
YoY Change -96.6%

Cashflow Statement

Concept 2023 Q3 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001421204
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
usd
RBSH Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification
usd
RBSH Common Stock Issued On Conversion Of Notes Payable And Derivative Liability
CommonStockIssuedOnConversionOfNotesPayableAndDerivativeLiability
usd
RBSH Debentures Converted To Common Stock
DebenturesConvertedToCommonStock
usd
RBSH Derivative Liability Extinguished Upon Conversion Of Notes Payable
DerivativeLiabilityExtinguishedUponConversionOfNotesPayable
usd
CY2022Q2 RBSH Loss On Conversion Of Debt
LossOnConversionOfDebt
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55331
dei Entity Registrant Name
EntityRegistrantName
REBUS HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0438951
dei Entity Address Address Line1
EntityAddressAddressLine1
2629 Townsgate Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 215
dei Entity Address City Or Town
EntityAddressCityOrTown
Westlake Village
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91361
dei City Area Code
CityAreaCode
818
dei Local Phone Number
LocalPhoneNumber
597-7552
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32132907 shares
CY2023Q2 us-gaap Cash
Cash
5000 usd
CY2022Q4 us-gaap Cash
Cash
5000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
9000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
5000 usd
CY2023Q2 us-gaap Assets
Assets
9000 usd
CY2022Q4 us-gaap Assets
Assets
5000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2120000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2078000 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1010000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
880000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5619000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5242000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
5619000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
5242000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32132907 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32132907 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32132907 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32132907 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60065000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60057000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65678000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65297000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5610000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5237000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
174000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
192000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
110000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
205000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
242000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
109000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
284000 usd
us-gaap Operating Expenses
OperatingExpenses
243000 usd
us-gaap Operating Expenses
OperatingExpenses
434000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-109000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-284000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-243000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-434000 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
156000 usd
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1060000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-130000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1459000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-24000 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-4000 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-21000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-8000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-54000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1365000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-381000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1971000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
43000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1365000 usd
us-gaap Net Income Loss
NetIncomeLoss
-381000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1971000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32132907 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32132907 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32132907 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31500860 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
160664535 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32132907 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32132907 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31500860 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5022000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
790000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-606000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4838000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1365000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6203000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5237000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
4000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-424000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5657000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5657000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
4000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
43000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
43000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5610000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5610000 usd
us-gaap Net Income Loss
NetIncomeLoss
-381000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1971000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-130000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1459000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-24000 usd
RBSH Imputed Interest On Notes Payable
ImputedInterestOnNotesPayable
8000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
54000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
187000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-32000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
60000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
16000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-446000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-446000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
711000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
265000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_800_eus-gaap--NatureOfOperations_z1zEo3xXXoM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_825_zVKb7ydwuwwi">BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rebus Holdings, Inc. (“we”, “us”, “our company”, “our”, “Rebus,” “Rebus Holdings,” or the “Company”) was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are focused on the research and development of novel targeted precision therapeutics for the treatment of cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine receptor A2B antagonist, is differentiated by its novel microparticle formulation that allows for better tumor infiltration and enhanced outcomes when administered intra-tumorally. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific targets found in each type of cancer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A antagonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor antagonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--BroadcastersLicenseAgreementCommitmentsDescription_c20230101__20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_z5Ud3RwAEyFi" title="Description of cancellation of a license agreement">In October 2020, pursuant to the cancellation of a license agreement whereby we previously licensed US Patent 9,593,118, we reacquired the exclusive right to such patent that covers both A2B and dual A2A/A2B antagonists. Accordingly, going forward our major focus will be to: (i) further characterization of the anti-cancer activity of our unique pipeline delivery platform containing A2B and dual A2A/A2B antagonists, leading to selection of a clinical candidate or candidates for an Investigative New Drug or IND enabling studies; and (ii) licensing and/or partnering our delivery platform and the A2B and dual A2A/A2B antagonists for further development.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to execute the business plan is contingent upon our ability to raise the necessary funds. We are currently using such funds to maintain our SEC reporting requirements, pay legal accounting and other professional fees, and to retain consultants and other personnel to develop the adenosine A2R antagonists and in preparation for an IND filing related to our unique delivery platform and portfolio of adenosine A2R antagonists for the treatment of certain solid tumors. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and seek business development opportunities with potential development partners and/or acquirors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 RBSH Working Capital Deficit
WorkingCapitalDeficit
5600000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66000000 usd
CY2023Q2 us-gaap Cash
Cash
5000 usd
CY2023Q2 RBSH Percentage Of Total Assets
PercentageOfTotalAssets
0.56 pure
CY2023Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
297000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_z3636zmDiWFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zyEJ5bGA2J99">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20000.00 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
200000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40000.00 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
200000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zrWEBiqaKesc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z4ZeKVEAO2s1">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash was $<span id="xdx_903_eus-gaap--Cash_iI_pp0p0_c20230630_zO0bAkGSQzi" title="Cash">5,000</span> and $<span id="xdx_903_eus-gaap--Cash_iI_pp0p0_c20221231_zcigMwv1fyu6" title="Cash">5,000</span> at June 30, 2023 and December 31, 2022, respectively. As of June 30, 2023 and December 31, 2022, there was no cash over the federally insured limit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Cash
Cash
5000 usd
CY2022Q4 us-gaap Cash
Cash
5000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
159027292 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
148966178 shares
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
43 usd
CY2023Q2 RBSH Income Attributable To Convertible Debentures And Preferred Stock
IncomeAttributableToConvertibleDebenturesAndPreferredStock
-179 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-136 usd
CY2023Q2 RBSH Basic Shares Outstanding
BasicSharesOutstanding
32132907 shares
CY2023Q2 RBSH Convertible Instuments
ConvertibleInstuments
128531628 shares
CY2023Q2 RBSH Diluted Shares Outstanding
DilutedSharesOutstanding
160664535 shares
CY2023Q2 RBSH Diluted Loss Per Share
DilutedLossPerShare
-0.00
CY2023Q2 RBSH Preferred Stock Fair Value Disclosures
PreferredStockFairValueDisclosures
713000 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1010000 usd
CY2022Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
285000 usd
CY2022Q4 RBSH Preferred Stock Fair Value Disclosures
PreferredStockFairValueDisclosures
595000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
880000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
880000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1124000 usd
RBSH Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassification
-507000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
130000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1459000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1010000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2076000 usd
CY2023Q2 RBSH Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
233000 usd
CY2022Q4 RBSH Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
233000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
561000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
519000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2120000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2078000 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
200000 usd
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1100000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-100000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1500000 usd
RBSH Common Stock Issued On Conversion Of Notes Payable And Derivative Liability
CommonStockIssuedOnConversionOfNotesPayableAndDerivativeLiability
790000 usd
RBSH Debentures Converted To Common Stock
DebenturesConvertedToCommonStock
462000 usd
RBSH Derivative Liability Extinguished Upon Conversion Of Notes Payable
DerivativeLiabilityExtinguishedUponConversionOfNotesPayable
507000 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1326000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1326000 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
1000000.0 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
900000 usd
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
As a result of past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $29,812.50 per share at June 30, 2023, (ii) our Series B Preferred Stock has been reduced to $0.0217 per share at June 30, 2023, (iii) 200 shares of our Series C preferred stock has been reduced to $1,125.00 per share at June 30, 2023, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $562.50 per share at June 30, 2023.
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32132907 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32132907 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
20363686 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
789699 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
461972 usd
RBSH Loss On Conversion Of Debt
LossOnConversionOfDebt
-23746 usd

Files In Submission

Name View Source Status
0001493152-23-029708-index-headers.html Edgar Link pending
0001493152-23-029708-index.html Edgar Link pending
0001493152-23-029708.txt Edgar Link pending
0001493152-23-029708-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rbsh-20230630.xsd Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rbsh-20230630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
rbsh-20230630_lab.xml Edgar Link unprocessable
rbsh-20230630_def.xml Edgar Link unprocessable
rbsh-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed